OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Markman on Unmet Needs in Rare Gynecologic Cancers

December 12th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, 2018 Giant of Cancer Care for Gynecologic Cancers, discusses unmet needs in rare gynecologic cancers.

Dr. Eber on the Utility of Cytoreductive Nephrectomy in mRCC

December 12th 2018

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses the utility of cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC).

Dr. Kolberg on Ensuring Confidence With Biosimilars in Oncology

December 12th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the importance of ensuring confidence with biosimilars in oncology.

Dr. Upadhyaya Discusses Drug Development for Pediatric Patients With Brain Tumors

December 12th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors.

Dr. Choueiri on Next Steps for Treatment in RCC

December 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses next steps for treatment in renal cell carcinoma.

Dr. Benson on Considerations for Advanced CRC Treatment

December 12th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the factors to consider when approaching treatment for a patient with advanced colorectal cancer.

Dr. Greten Discusses the Impact of the Gut Microbiome on Liver Tumors

December 12th 2018

Tim F. Greten, MD, senior investigator, Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, discusses the impact of the gut microbiome on liver tumors.

Dr. Seymour on Updated Findings From the MURANO Trial in CLL

December 12th 2018

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the updated findings from the MURANO trial presented at the 2018 ASH Annual Meeting.

Dr. Esteva on the Trastuzumab Biosimilar Candidate CT-P6 in HER2+ Breast Cancer

December 11th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the efficacy and safety of the trastuzumab (Herceptin) biosimilar candidate CT-P6 in HER2-positive breast cancer.

Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast Cancer

December 11th 2018

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the rationale and results of the phase III KATHERINE trial in HER2-positive breast cancer.

Dr. O'Regan on Future of Chemotherapy in Breast Cancer

December 11th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

Dr. Madduri on Treatment After CAR T Cells in Myeloma

December 11th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Dr. Vaena on the Importance of Risk Stratification in Prostate Cancer

December 11th 2018

Daniel Vaena, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of risk stratification in prostate cancer.

Dr. Bardia on Potential Concerns With Biosimilars in Breast Cancer

December 11th 2018

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, discusses potential concerns regarding the use of biosimilars in the breast cancer space.

Common Treatment-Related Toxicities in mRCC

December 11th 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses common treatment-related toxicities in metastatic renal cell carcinoma (RCC).

Dr. Sabari Compares Liquid and Tissue Biopsies in NSCLC

December 11th 2018

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.

Dr. Somer on Immunotherapy Combinations in mRCC

December 8th 2018

Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in metastatic renal cell carcinoma.

Dr. Borgen Discusses the Global Impact of Biosimilars

December 8th 2018

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the potential global impact of biosimilars in oncology.

Dr. Fowke on Overcoming Racial Disparity in Prostate Cancer

December 7th 2018

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses ways to overcome racial disparity in prostate cancer.

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLC

December 7th 2018

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.